<DOC>
	<DOCNO>NCT02027155</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , rising-dose study single IV dose AR09 healthy subject . Each infusion occur 10 minute .</brief_summary>
	<brief_title>Phase I Rising-dose Study Assess Tolerability , Safety , Pharmacokinetics , Pharmacodynamics AR09</brief_title>
	<detailed_description>Each subject complete Screening , Baseline , Treatment , Follow-Up Phases . The Screening Phase conduct outpatient basis within 30 day , le 3 day , prior start Baseline Phase . The Baseline Phase consist clinical research unit ( CRU ) admission final qualification assessment . The Treatment Phase comprise dose Day 1 , post-treatment safety pharmacodynamic assessment , blood urine collection . Subjects may discharge approximately 24 hour study drug administration Day 2 , provide Modified Aldrete Score designate discharge criterion clinically acceptable Investigator . The Follow-Up Phase occur Study Day 5 ( ± 1 day ) .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Males/females 18 50 year age , inclusive ; Body mass index 18 30 kg/m2 , inclusive . All female must negative serum beta human chorionic gonadotropin test result screen negative urine pregnancy test result baseline . Female subject must either postmenopausal , surgically sterile use acceptable method contraception . Acceptable surgical sterilization technique hysterectomy , bilateral tubal ligation surgery least 6 month prior dose bilateral oophorectomy surgery least 2 month prior dose . Acceptable method contraception intrauterine device , contraceptive implant , oral contraceptive ( stable dose hormonal contraceptive product least 12 week prior dose ) , vasectomized partner doublebarrier method ( condom + spermicide / diaphragm + spermicide ) . Willing able provide voluntary , write informed consent . Acute illness within 2 week prior dose ; History chronic illness evidence significant organic psychiatric disease medical history physical examination , opinion Investigator would confound study result present risk subject ; History clinically significant pulmonary condition , within last 2 year require admission hospital ; Spirometry force expiratory volume one second ( FEV1 ) force vital capacity ( FVC ) ratio le 70 % ; If female , pregnant lactating ; Clinically significant illness abnormality physical examination , ECG , include measure time start Q wave end T wave heart 's electrical cycle ( QTc interval ) &gt; 440 msec , Screening predose 12lead ECG ; Resting heart rate awake &lt; 45 &gt; 90 b/m ; Laboratory value ( ) outside laboratory reference range consider clinically significant ( clinical chemistry , hematology , coagulation , ACTH , urinalysis , pregnancy test ) . Presence type I type II diabetes ; History severe allergic reaction drug multiple food/drug allergy ; Subjects formal diagnosis obstructive sleep apnea score &gt; 3 STOPBang questionnaire ( see Appendix 4 ) ; Reported chronic ( regular use &gt; 1 month ) use medication kind ( except contraceptive describe inclusion criterion ) , unless approve Sponsor ; Reported use prescription drug within 14 day prior dose , nonprescription drug vitamin within 7 day prior dose , know enzymeinducer , enzymeinhibitor , investigational drug within 30 day prior dose , report chronic exposure enzymeinducers paint solvent pesticide within 30 day dose , unless approve Sponsor ; hormonal contraceptive permit subject use least 12 week prior dose ; History alcohol illicit drug abuse within past two year , current report average alcohol intake &gt; two alcoholic drink per day ( e.g. , 24 oz . beer , 10 oz . wine , 3 oz . hard liquor ) ; Regular use tobacco nicotine containing product within 1 year study entry ; Average consumption ≥ 6 caffeine contain beverage per day ; Consumption alcohol within 72 hour prior dose , positive qualitative urine drug cotinine screen , positive oral screen presence alcohol ; Consumption herbal supplement , grapefruit grapefruit juice within 14 day dose ; Blood donation approximately 400 mL within 4 week plasma donation within 2 week prior dose ; Received investigational product within 30 day first dose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>